x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:29:56

William Blair biotech analyst Andy Hsieh takes stock...

BiotechTV - News ·

2025/06/26

He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide. Plus, thoughts on Viking's program as it enters phase 3.

en-us

00:16:43

Checking in with the co-founders of Amylyx...

BiotechTV - News ·

2025/06/25

Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study that will read out in 1H26. Plus, updates on AMX0035 in Wolfram Syndrome and Progressive Supranuclear Palsy, and an ALS program targeting calpain-2 that will have initial data later this year.

en-us

00:11:24

Oxford, UK based Pathios Therapeutics is targeting...

BiotechTV - News ·

2025/06/24

CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how cancer patients who genetically have low signaling are seen to have better outcomes in than other genotypes.

en-us

00:08:46

Emeryville based Fauna Bio launched Fauna Brain, an...

BiotechTV - News ·

2025/06/20

Co-Founder Linda Goodman describes the product and the numerous components that go into the scoring.

en-us

00:12:48

The Co-Director of Cardiff University's Medicines...

BiotechTV - News ·

2025/06/20

Simon Ward, Co-Director along with John Atack, describes the founding of the institue and why Cardiff University was a good fit. He describes the goal, to get science through biotech's "valley of death" and to help turn more discoveries from the university into medicines, and how they partner with industry.

en-us

00:17:52

SV Health Investors Managing Partner Kate Bingham...

BiotechTV - News ·

2025/06/20

Kate Bingham describes the type of investments SV makes, which was in the news this week for being the founding investor of the neuropsych company Draig Therapeutics that exited stealth with $140M. Plus, having previously served as the chair of the government's Vaccine Taskforce during COVID, she also shares her thoughts on the evironment in the UK and the MHRA.

en-us

00:10:01

AI News: Alameda based Infinimmune launched its...

BiotechTV - News ·

2025/06/19

Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an ideal way to engineer antibodies, and he describes why he believes the model will be successful for drug development both inside and outside of autoimmune conditions.

en-us

00:10:18

Draig Therapeutics launched from stealth today with a...

BiotechTV - News ·

2025/06/18

An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University Professors John Atack and Simon Ward. She highlights how unusual it is to have clinical proof of concept data already while raising a series A, and why she believes Draig will make a difference for patients.

en-us

00:09:21

BIO International 2025: Sweden's Alligator has a...

BiotechTV - News ·

2025/06/18

CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial design. He desribes looking for a partner, and what other cancers the therapy could have utility in. Plus, a next-generation bi-specific targeting CD40 and CEACAM5.

en-us

00:08:30

BIO International 2025: The new CEO of Sweden's Hansa...

BiotechTV - News ·

2025/06/18

Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa it trying to expand on it. Plus, development work in Guillain-Barré syndrome and gene therapy.

en-us

00:09:01

BIO International 2025: Oppenheimer's Head of...

BiotechTV - News ·

2025/06/17

He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he cautions that it is very difficult to get early-stage development funded and that companies need to be creative to get phase 1 studies done.

en-us

00:10:02

BIO International 2025: Perspective Therapeutics CEO...

BiotechTV - News ·

2025/06/17

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

en-us

00:09:21

BIO International 2025: CEO Paul Hastings discusses...

BiotechTV - News ·

2025/06/17

He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will share a data on everything before the end of the year.

en-us

00:08:02

BIO International 2025: Germany's Aicuris, a company...

BiotechTV - News ·

2025/06/17

CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with Merck/MSD, and R&D products targeting HSV and BKV.

en-us

00:11:58

BIO International 2025: UroGen CEO Liz Barrett...

BiotechTV - News ·

2025/06/17

She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.

en-us

00:06:37

BIO International 2025: eGenesis CEO Mike Curtis...

BiotechTV - News ·

2025/06/17

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

en-us

00:14:04

BIO International 2025: Stifel's Tim Opler comments...

BiotechTV - News ·

2025/06/16

He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his take on the potential most favored nation policy, companies with negative enterprise values, and China competition.

en-us

00:14:02

BIO International 2025: Ocugen CEO Shankar Musunuri...

BiotechTV - News ·

2025/06/16

He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA today), and geographic atrophy.

en-us

00:16:03

EHA 2025: Arcellx CEO Rami Elghandour discusses the...

BiotechTV - News ·

2025/06/14

He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus learnings from year two of a physician survey, and his current take on CAR-T for autoimmune and CD123 for AML.

en-us

00:18:21

EHA 2025: The CEO of Ascentage Pharma, which had its...

BiotechTV - News ·

2025/06/14

Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a third-generation TKI, and highiglights Bcl-2 and EED.

en-us

432 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter